Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00492089
Other study ID # NCI-2009-00256
Secondary ID NCI-2009-00256CD
Status Completed
Phase Phase 2
First received June 25, 2007
Last updated April 21, 2014
Start date June 2007
Est. completion date August 2010

Study information

Verified date April 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain for primary brain tumor, meningioma, or head and neck cancer.


Description:

PRIMARY OBJECTIVE:

I. Determine to what extent bevacizumab can reduce active radiation toxicity to the CNS in patients who have undergone cranial irradiation for primary brain neoplasm, meningioma, or head and neck cancer.

SECONDARY OBJECTIVES:

I. Determine to what extent this drug can reduce dexamethasone dependence in these patients.

II. Determine to what extent this drug can improve neurologic function in these patients.

III. Determine to what extent this drug can improve quality of life of these patients.

OUTLINE: This is a randomized, placebo-controlled, crossover, double-blind study. Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.

Patients in arm II who have failed to respond to treatment at 6 or 12 weeks may cross over to arm I and receive 2 courses of bevacizumab as in arm I. Patients in arm I (including crossover patients) who have responded to treatment may receive 2 additional courses of bevacizumab.

Patients undergo MRI after courses 2 and 4.

Quality of life and neurologic function are assessed at baseline, periodically during study treatment, and at 12 and 24 weeks after completion of study treatment.

After completion of study treatment, patients are followed at 12 and 24 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date August 2010
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- No evidence of bleeding diathesis or coagulopathy

- Fertile patients must use effective contraception during and for >= 2 months after completion of study therapy

- No diarrhea >= grade 1

- Histologically confirmed primary brain neoplasm, meningioma, or head and neck cancer [WHO grade 2 or 3 disease--no WHO grade 4 primary brain neoplasms (i.e., glioblastoma or gliosarcoma)]

- Patients with head and neck cancer must not have any of the following:

- Evidence of metastatic disease

- Evidence of tumor invasion to major vessels (e.g., the carotid)

- History of bleeding related to tumor or radiotherapy during or after completion of radiotherapy

- Must have undergone cranial irradiation

- Must have radiographic evidence to support the diagnosis of radiation necrosis and/or surgical biopsy evidence of necrosis without tumor within the past 2 months

- Must have evidence of progressive neurologic signs or symptoms appropriate to the location of the radiation necrosis

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days

- No significant traumatic injury within the past 28 days

- No evidence of active CNS hemorrhage

- Karnofsky performance status 60-100%

- No clinically significant cardiovascular disease, including any of the following:

- Inadequately controlled hypertension (i.e., systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg despite antihypertensive medication)

- Large vessel cerebrovascular accident within the past 6 months

- Myocardial infarction or unstable angina within the past 6 months

- No clinically significant cardiovascular disease, including any of the following:

- NYHA class II-IV congestive heart failure

- Serious or inadequately controlled cardiac arrhythmia

- Significant vascular disease (e.g., aortic aneurysm or history of aortic dissection)

- Clinically significant peripheral vascular disease

- At least 6 months since prior radiotherapy

- Platelet count > 75,000/mm^3

- Granulocyte count > 1,500/mm^3

- Creatinine < 1.0 times ULN

- AST < 2.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Prior chemotherapy for tumor allowed

- Prior tyrosine kinase inhibitors of VEGF receptor (VEGFR) allowed

- More than 28 days since prior and no concurrent major surgical procedure or open biopsy

- Concurrent dexamethasone allowed provided patient is on a stable dose for >= 1 week prior to study entry

- Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed provided the following criteria are met:

- In-range INR (usually between 2 and 3) and patient is on a stable dose of oral anticoagulant for 1 week or on a stable dose of low molecular weight heparin

- No active bleeding or pathological condition that carries a high risk of bleeding

- Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed provided the following criteria are met: No evidence of serious or nonhealing wound, ulcer, or bone fracture

- No concurrent chemotherapy or tyrosine kinase inhibitors of VEGFR

- No prior bevacizumab

- More than 7 days since prior core biopsy

- History of seizures allowed provided the patient is receiving anticonvulsant therapy

- Hemoglobin >= 9.0 g/dL

- Bilirubin =< 1.5 times upper limit of normal (ULN)

- No other concurrent investigational agents

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care


Related Conditions & MeSH terms

  • Adult Anaplastic Astrocytoma
  • Adult Anaplastic Ependymoma
  • Adult Anaplastic Meningioma
  • Adult Anaplastic Oligodendroglioma
  • Adult Brain Stem Glioma
  • Adult Central Nervous System Germ Cell Tumor
  • Adult Choroid Plexus Tumor
  • Adult Diffuse Astrocytoma
  • Adult Ependymoma
  • Adult Grade II Meningioma
  • Adult Grade III Meningioma
  • Adult Malignant Hemangiopericytoma
  • Adult Mixed Glioma
  • Adult Oligodendroglioma
  • Adult Papillary Meningioma
  • Adult Pineocytoma
  • Astrocytoma
  • Brain Neoplasms
  • Carcinoma
  • Carcinoma, Adenoid Cystic
  • Carcinoma, Basal Cell
  • Carcinoma, Squamous Cell
  • Choroid Plexus Neoplasms
  • Ependymoma
  • Esthesioneuroblastoma, Olfactory
  • Glioma
  • Granuloma
  • Hemangiopericytoma
  • Laryngeal Diseases
  • Laryngeal Neoplasms
  • Malignant Neoplasm
  • Meningeal Melanocytoma
  • Meningioma
  • Nasopharyngeal Neoplasms
  • Neoplasms
  • Oligodendroglioma
  • Oropharyngeal Neoplasms
  • Papilloma
  • Paranasal Sinus Neoplasms
  • Radiation Toxicity
  • Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
  • Recurrent Adult Brain Tumor
  • Recurrent Basal Cell Carcinoma of the Lip
  • Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
  • Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
  • Recurrent Lymphoepithelioma of the Nasopharynx
  • Recurrent Lymphoepithelioma of the Oropharynx
  • Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
  • Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
  • Recurrent Salivary Gland Cancer
  • Recurrent Squamous Cell Carcinoma of the Hypopharynx
  • Recurrent Squamous Cell Carcinoma of the Larynx
  • Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Recurrent Squamous Cell Carcinoma of the Nasopharynx
  • Recurrent Squamous Cell Carcinoma of the Oropharynx
  • Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
  • Recurrent Verrucous Carcinoma of the Larynx
  • Recurrent Verrucous Carcinoma of the Oral Cavity
  • Salivary Gland Neoplasms
  • Solitary Fibrous Tumors
  • Stage I Adenoid Cystic Carcinoma of the Oral Cavity
  • Stage I Basal Cell Carcinoma of the Lip
  • Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
  • Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
  • Stage I Lymphoepithelioma of the Nasopharynx
  • Stage I Lymphoepithelioma of the Oropharynx
  • Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
  • Stage I Mucoepidermoid Carcinoma of the Oral Cavity
  • Stage I Salivary Gland Cancer
  • Stage I Squamous Cell Carcinoma of the Hypopharynx
  • Stage I Squamous Cell Carcinoma of the Larynx
  • Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage I Squamous Cell Carcinoma of the Nasopharynx
  • Stage I Squamous Cell Carcinoma of the Oropharynx
  • Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
  • Stage I Verrucous Carcinoma of the Larynx
  • Stage I Verrucous Carcinoma of the Oral Cavity
  • Stage III Adenoid Cystic Carcinoma of the Oral Cavity
  • Stage III Basal Cell Carcinoma of the Lip
  • Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
  • Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
  • Stage III Lymphoepithelioma of the Nasopharynx
  • Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
  • Stage III Mucoepidermoid Carcinoma of the Oral Cavity
  • Stage III Salivary Gland Cancer
  • Stage III Squamous Cell Carcinoma of the Hypopharynx
  • Stage III Squamous Cell Carcinoma of the Larynx
  • Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage III Squamous Cell Carcinoma of the Nasopharynx
  • Stage III Squamous Cell Carcinoma of the Oropharynx
  • Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
  • Stage III Verrucous Carcinoma of the Larynx
  • Stage III Verrucous Carcinoma of the Oral Cavity
  • Stage IV Adenoid Cystic Carcinoma of the Oral Cavity
  • Stage IV Basal Cell Carcinoma of the Lip
  • Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
  • Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
  • Stage IV Lymphoepithelioma of the Nasopharynx
  • Stage IV Lymphoepithelioma of the Oropharynx
  • Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
  • Stage IV Mucoepidermoid Carcinoma of the Oral Cavity
  • Stage IV Salivary Gland Cancer
  • Stage IV Squamous Cell Carcinoma of the Hypopharynx
  • Stage IV Squamous Cell Carcinoma of the Larynx
  • Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage IV Squamous Cell Carcinoma of the Nasopharynx
  • Stage IV Squamous Cell Carcinoma of the Oropharynx
  • Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
  • Stage IV Verrucous Carcinoma of the Larynx
  • Stage IV Verrucous Carcinoma of the Oral Cavity

Intervention

Drug:
bevacizumab
Given IV
placebo
Given IV
Procedure:
magnetic resonance imaging

quality-of-life assessment


Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Response ( > 25% Reduction in T2 Flair) From Baseline to Evaluation at 6 Weeks Post Treatment Change in magnetic resonance imaging (MRI) from baseline to evaluation at 6 weeks for participants where MRI changes are based on the size of edema (T2 FLAIR) and Gd-contrast enhancement (lesion diameter and perfusion/dynamic). A 25% reduction in T2 flair volume constitutes a response for study. Baseline to 12 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Active, not recruiting NCT02243592 - Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Completed NCT03445572 - Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer N/A
Active, not recruiting NCT02860039 - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Phase 2
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT01635413 - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial) N/A
Completed NCT00026169 - Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure Phase 1
Recruiting NCT04534075 - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial Phase 3
Active, not recruiting NCT01806129 - Reproductive Health Program in Patients With Cancer N/A
Recruiting NCT03915717 - Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Recruiting NCT02280161 - Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Terminated NCT00532064 - Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
Completed NCT04990882 - FAPI PET/CT Prospective Interobserver Agreement
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05886764 - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials N/A
Completed NCT01432431 - Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff N/A
Completed NCT01506440 - Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy